$1.43 Billion is the total value of Visium Asset Management, LP's 989 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CYNA | Cynapsus Therapeutics Inc | $12,563,000 | +40.8% | 750,000 | 0.0% | 0.88% | +478.3% | |
| BLVDU | Boulevard Acquisition Corp II | $11,984,000 | -0.6% | 1,211,702 | 0.0% | 0.84% | +309.3% | |
| CLACU | Capitol Acquisition Corp III | $9,942,000 | +0.7% | 1,002,231 | 0.0% | 0.70% | +314.3% | |
| SRAQU | Silver Run Acquisition Corp | $8,214,000 | -3.6% | 822,973 | 0.0% | 0.58% | +296.6% | |
| HCACU | Hennessy Capital Acquisition Corp II | $2,325,000 | -5.3% | 250,051 | 0.0% | 0.16% | +288.1% | |
| ODP | Office Depot Inccall | $169,000 | -53.6% | 51,200 | 0.0% | 0.01% | +100.0% | |
| CYH | Community Health Systems Inc | $1,000 | 0.0% | 233,966 | 0.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Compass TPM LLC #1
- Compass Offshore TPM LP #2
- Catalyst Investment Management Co., LLC #3
- JG Asset, LLC #4
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 13 | Q2 2016 | 1.9% |
| GRIFOLS SA-ADR | 13 | Q2 2016 | 1.3% |
| YAHOO! INC | 13 | Q2 2016 | 1.6% |
| DANAHER CORP | 13 | Q2 2016 | 0.8% |
| American International Group Inc | 13 | Q2 2016 | 0.7% |
| ASHLAND INC | 13 | Q2 2016 | 0.4% |
| B/E AEROSPACE INC | 13 | Q2 2016 | 0.3% |
| HONEYWELL INTERNATIONAL INC | 13 | Q2 2016 | 0.4% |
| E*TRADE FINANCIAL CORP | 13 | Q2 2016 | 0.6% |
| HEALTHSOUTH CORP | 13 | Q2 2016 | 0.2% |
View Visium Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ALBANY MOLECULAR RESEARCH INCSold out | February 14, 2017 | 0 | 0.0% |
| APPLIED GENETIC TECHNOLOGIES CORPSold out | February 14, 2017 | 0 | 0.0% |
| AQUINOX PHARMACEUTICALS, INCSold out | February 14, 2017 | 0 | 0.0% |
| Ascendis Pharma A/SSold out | February 14, 2017 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2017 | 0 | 0.0% |
| Axovant Sciences Ltd.Sold out | February 14, 2017 | 0 | 0.0% |
| Bioblast Pharma Ltd.Sold out | February 14, 2017 | 0 | 0.0% |
| CONMED CORPSold out | February 14, 2017 | 0 | 0.0% |
| CymaBay Therapeutics, Inc.Sold out | February 14, 2017 | 0 | 0.0% |
| Enzymotec Ltd.Sold out | February 14, 2017 | 0 | 0.0% |
View Visium Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2017-02-14 |
| SC 13G/A | 2017-02-14 |
| SC 13G/A | 2017-02-14 |
| SC 13G/A | 2017-02-14 |
| SC 13G/A | 2017-02-14 |
| SC 13G/A | 2017-02-14 |
| SC 13G/A | 2017-02-14 |
| SC 13G/A | 2017-02-14 |
| SC 13G/A | 2017-02-14 |
| SC 13G/A | 2017-02-14 |
View Visium Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.